Mycophenolate Mofetil Tablets and Zovirax (Acyclovir Suspension)
Determining the interaction of Mycophenolate Mofetil Tablets and Zovirax (Acyclovir Suspension) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Coadministration with mycophenolic acid may increase the plasma concentrations of acyclovir. The mechanism of interaction has not been described. In 15 healthy subjects, coadministration of a single oral dose each of mycophenolate mofetil (1 gram) and acyclovir (800 mg) increased the peak plasma concentration (Cmax), area under the concentration-time curve (AUC) and time to reach Cmax (Tmax) of acyclovir by 40%, 31% and 0.38 hour, respectively, compared to administration of acyclovir alone. In contrast, coadministration of mycophenolate mofetil with valacyclovir (2 gram) did not significantly alter acyclovir pharmacokinetics with the exception of a 0.5 hour decrease in Tmax. During coadministration with acyclovir or valacyclovir, pharmacokinetics of mycophenolic acid and its glucuronide metabolite, MPAG, were generally not significantly altered, although the AUC of MPAG decreased by 12% with valacyclovir. None of these changes are considered clinically relevant in healthy individuals. However, because both MPAG and acyclovir plasma concentrations are increased in the presence of renal impairment, the potential exists for the two drugs to compete for active tubular secretion, further increasing the concentrations of both drugs. Caution may be appropriate in patients with decreased renal function.
- "Product Information. Myfortic (mycophenolic acid)." Novartis Pharmaceuticals, East Hanover, NJ.
- "Product Information. CellCept (mycophenolate mofetil)." Roche Laboratories, Nutley, NJ.
- Gimenez F, Foeillet E, Bourdon O, et al. "Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects." Clin Pharmacokinet 43 (2004): 685-92
Generic Name: mycophenolate mofetil
Brand name: Cellcept, Myfortic, MMF
Synonyms: Mycophenolate mofetil (oral/injection), Mycophenolate
Generic Name: acyclovir
Brand name: Sitavig, Zovirax
Synonyms: Zovirax
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Mycophenolate Mofetil Tablets-Zovirax Cream
- Mycophenolate Mofetil Tablets-Zovirax Injection
- Mycophenolate Mofetil Tablets-Zovirax Ointment
- Mycophenolate Mofetil Tablets-Zovirax Oral, Intravenous
- Mycophenolate Mofetil Tablets-Zovirax Suspension
- Mycophenolate Mofetil Tablets-Zovirax Topical
- Zovirax (Acyclovir Suspension)-Mycophenolate sodium
- Zovirax (Acyclovir Suspension)-Mycophenolate Suspension
- Zovirax (Acyclovir Suspension)-Mycophenolate Tablets
- Zovirax (Acyclovir Suspension)-Mycophenolate Tablets Delayed Release
- Zovirax (Acyclovir Suspension)-Mycophenolic acid
- Zovirax (Acyclovir Suspension)-Mycophenolic Acid Delayed-Release Tablets